We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase ( PI3K ) catalytic subunit ( PIK3CA ) correlates with response to neoadjuvant human epidermal growth factor receptor 2 ( HER2 ) - targeted therapies in patients with breast cancer .